Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - Instil Bio ( NASDAQ:TIL )

3 days ago

Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer ( NSCLC ) Global registrational strategy in first-line triple-negative breast cancer ( TNBC ) Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC ...

Ticker	Sentiment	Impact
TIL	Neutral	15 %